

F. No. CT/11/11-DCG (I)
Directorate General of Health Services
Office of Drugs Controller General (India)
(New Drug Division)

300/20-1-11
FDA Bhawan New Delhi
Dated:

19 MAY 2011

To

M/s. Novartis Healthcare Pvt. Ltd.,
Sandoz House, Dr. Annie Besant Road,
Worli, Mumbai - 400 018.

Subject: Clinical trial with Aliskiren (Protocol No: CSPP100G2301) - regarding

CT No: CT/Drugs/60/2011

Reference: Your letter no nil dated 19/01/11.

Sir,

This Directorate has no objection to your conducting clinical trials with the said drug under the supervision of the investigators mentioned in your letter and as per the protocol forwarded to this Directorate. At the time of submitting clinical trials reports to this Directorate for evaluation you are required to comply with the following requirements:-

1. Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.
2. Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multi-centric).
3. Approval of the Ethical Committee of the concerned center/institution for conducting the clinical trial with the said drug.

You are requested to submit to this Directorate an annual status report on each clinical trial viz. ongoing, completed or terminated. In case the trial is terminated the reasons for the same should be communicated to this Directorate. In case any unexpected serious adverse reaction is observed during trial, the same should be immediately communicated.

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.


You are also requested to follow Ethical aspects of the clinical trial as described in the booklet "Ethical Guidelines for Biomedical Research on Human Subjects" published by Indian Council of Medical Research (ICMR), New Delhi, and 'GCP' guideline issued by this Department and to obtain Ethical Committee clearance of the Institute before initiation of the study. Ethical Committee clearance should be obtained before initiation of the study.

It is mandatory to register this clinical trial at ICMR clinical trial registry at www.ctri.in in before enrolling first patient in the study.

In future correspondence, you may intimate this Directorate that you have registered the study as mentioned above and also mention the registration number in all your correspondences.

In case of study related injury or death, you will provide complete medical care as well as compensation for the injury or death and statement to this effect should be incorporated in the Informed Consent Form. Further in case of such injuries or deaths the details of compensation provided should be intimated to this Directorate.

Yours faithfully,


(Dr. Surinder Singh)
Drugs Controller General (India)

F. No. CT/20/11- DCG (I)
Directorate General of Health Services
Office of Drugs Controller General (India)
(New Drug Division)

17907/12-4-11
FDA Bhawan New Delhi
Dated: 19 MAY 2011

To

M/s. Lotus Labs Pvt. Ltd.,
No 07, Jasma Bhavan Road, Millers Tank Bed Area,
Opp. Gurunanak Bhavan, Vasanthanagar, Bangalore -560052.

Subject: Clinical trial with Adapalene & Benzoyl Peroxide Topical Gel (Protocol No: ACTA/ADAP/BP/2010) – regarding.

CT No: CT/Drugs/69/2011

Reference: Your letter no LL/RA/285/2011 dated 15/04/11.

Sir,

This Directorate has no objection to your conducting clinical trials with the said drug under the supervision of the investigators mentioned in your letter and as per the protocol forwarded to this Directorate **subject to condition that the number of subjects to be enrolled from India in the study should not be more than 275**. At the time of submitting clinical trials reports to this Directorate for evaluation you are required to comply with the following requirements:-

1. Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.
2. Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multi-centric).
3. Approval of the Ethical Committee of the concerned center/institution for conducting the clinical trial with the said drug.

You are requested to submit to this Directorate an annual status report on each clinical trial viz. ongoing, completed or terminated. In case the trial is terminated the reasons for the same should be communicated to this Directorate. In case any unexpected serious adverse reaction is observed during trial, the same should be immediately communicated.

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.


You are also requested to follow Ethical aspects of the clinical trial as described in the booklet "Ethical Guidelines for Biomedical Research on Human Subjects" published by Indian Council of Medical Research (ICMR), New Delhi, and 'GCP' guideline issued by this Department and to obtain Ethical Committee clearance of the Institute before initiation of the study. Ethical Committee clearance should be obtained before initiation of the study.

It is mandatory to register this clinical trial at ICMR clinical trial registry at www.ctri.in in before enrolling first patient in the study.

In future correspondence, you may intimate this Directorate that you have registered the study as mentioned above and also mention the registration number in all your correspondences.

In case of study related injury or death, you will provide complete medical care as well as compensation for the injury or death and statement to this effect should be incorporated in the Informed Consent Form. Further in case of such injuries or deaths the details of compensation provided should be intimated to this Directorate.

Yours faithfully,


(Dr. Surinder Singh)
Drugs Controller General (India)

F. No. CT/248/10-DCG (I)
Directorate General of Health Services
Office of Drugs Controller General (India)
(New Drug Division)

9438/28-2-11
FDA Bhawan New Delhi

Dated: 11 9 MAY 2011

To
M/s. Quintiles Research (India) Pvt. Ltd.,
2B, Nitesh Broadway, 9/3,
M.G. Road, Bangalore-560 001.

Subject: Clinical trial with Fostamatinib Disodium (Protocol No: D4300C00001) - regarding
CT No: CT/Drugs/61/2011

Reference: Your letter no QR/RA/ 329/2011/01 dated 24/02/11.

Sir,

This Directorate has no objection to your conducting clinical trials with the said drug under the supervision of the investigators mentioned in your letter and as per the protocol forwarded to this Directorate. At the time of submitting clinical trials reports to this Directorate for evaluation you are required to comply with the following requirements:-

1. Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.
2. Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multi-centric).
3. Approval of the Ethical Committee of the concerned center/institution for conducting the clinical trial with the said drug.

You are requested to submit to this Directorate an annual status report on each clinical trial viz. ongoing, completed or terminated. In case the trial is terminated the reasons for the same should be communicated to this Directorate. In case any unexpected serious adverse reaction is observed during trial, the same should be immediately communicated.

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.


You are also requested to follow Ethical aspects of the clinical trial as described in the booklet "Ethical Guidelines for Biomedical Research on Human Subjects" published by Indian Council of Medical Research (ICMR), New Delhi, and 'GCP' guideline issued by this Department and to obtain Ethical Committee clearance of the Institute before initiation of the study. Ethical Committee clearance should be obtained before initiation of the study.

It is mandatory to register this clinical trial at ICMR clinical trial registry at www.ctri.in in before enrolling first patient in the study.

In future correspondence, you may intimate this Directorate that you have registered the study as mentioned above and also mention the registration number in all your correspondences.

In case of study related injury or death, you will provide complete medical care as well as compensation for the injury or death and statement to this effect should be incorporated in the Informed Consent Form. Further in case of such injuries or deaths the details of compensation provided should be intimated to this Directorate.

Yours faithfully,


(Dr. Surinder Singh)
Drugs Controller General (India)

F. No. CT/84/10-DCG (I)
Directorate General of Health Services
Office of Drugs Controller General (India)
(New Drug Division)

4817-112-16-10
FDA Bhawan New Delhi
Dated: 11/05/2011

To
M/s. Bioserve Clinical Research Pvt. Ltd.,
#6-56/6/1/A, Opp. IDPL Factory, Balanagar,
Hyderabad - 500 037.

Subject: Clinical trial with Pentosan Poly sulfate Sodium (Protocol No: CT003/09) - regarding.
CT No: CT/Drugs/58/2011

Reference: Your letter no nil dated 07/10/10.

Sir,

This Directorate has no objection to your conducting clinical trials with the said drug under the supervision of the investigators mentioned in your letter and as per the protocol forwarded to this Directorate. At the time of submitting clinical trials reports to this Directorate for evaluation you are required to comply with the following requirements:-

1. Submit complete report of clinical trials as per the approved protocol from the individual investigator duly signed by him along with his observations/remarks on the drug.
2. Indicating the date of commencement and conclusion of the clinical trial at each center (in case the study is multi-centric).
3. Approval of the Ethical Committee of the concerned center/institution for conducting the clinical trial with the said drug.

You are requested to submit to this Directorate an annual status report on each clinical trial viz. ongoing, completed or terminated. In case the trial is terminated the reasons for the same should be communicated to this Directorate. In case any unexpected serious adverse reaction is observed during trial, the same should be immediately communicated.

It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.


You are also requested to follow Ethical aspects of the clinical trial as described in the booklet "Ethical Guidelines for Biomedical Research on Human Subjects" published by Indian Council of Medical Research (ICMR), New Delhi, and 'GCP' guideline issued by this Department and to obtain Ethical Committee clearance of the Institute before initiation of the study. Ethical Committee clearance should be obtained before initiation of the study.

It is mandatory to register this clinical trial at ICMR clinical trial registry at www.ctri.in in before enrolling first patient in the study.

In future correspondence, you may intimate this Directorate that you have registered the study as mentioned above and also mention the registration number in all your correspondences.

In case of study related injury or death, you will provide complete medical care as well as compensation for the injury or death and statement to this effect should be incorporated in the Informed Consent Form. Further in case of such injuries or deaths the details of compensation provided should be intimated to this Directorate.

Yours faithfully,


(Dr. Surinder Singh)
Drugs Controller General (India)